A new millennium conundrum: How to use a powerful class of influenza anti-neuraminidase drugs (NAIs) in the community

Journal of Antimicrobial Chemotherapy

Volumn 53, Issue 2, 2004, Pages 133-136

  Oxford, John ^a   Balasingam, Shobana ^a   Lambkin, Rob ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Antivirals; Epidemics; Pandemics; Respiratory viruses

Indexed keywords

2 DEOXY 2,3 DEHYDRO N TRIFLUOROACETYLNEURAMINIC ACID; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ACICLOVIR; AMANTADINE; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; CIDOFOVIR; NEURAMINIC ACID DERIVATIVE; OSELTAMIVIR; PLACEBO; PROTEINASE INHIBITOR; RIBAVIRIN; RIMANTADINE; SIALIDASE; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; ZANAMIVIR;

ANTIBIOTIC THERAPY; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; COMMUNITY CARE; DRUG CLASSIFICATION; DRUG MECHANISM; DRUG SENSITIVITY; DRUG TARGETING; DRUG TOLERABILITY; DRUG USE; ECONOMIC ASPECT; ENZYME ACTIVITY; EPIDEMIC; FAMILY HEALTH; HEALTH CARE PLANNING; HUMAN; INFECTION PREVENTION; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS B; LABORATORY TEST; MEDICAL DOCUMENTATION; MORTALITY; NAUSEA AND VOMITING; NONHUMAN; PANIC; PRESCRIPTION; SEVERE ACUTE RESPIRATORY SYNDROME; SYMPTOMATOLOGY; VIRUS CELL INTERACTION; VIRUS EXCRETION; VIRUS INFECTION; VIRUS INHIBITION; VIRUS MUTANT; VIRUS VIRULENCE;

ANTIVIRAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DISEASE OUTBREAKS; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; HUMANS; INFLUENZA, HUMAN; NEURAMINIDASE;

EID: 1242285459     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh037     Document Type: Article

References (17)

1. Oxford, J. S. (2000). Influenza A pandemics of the 20th century with special reference to 1918: virology, pathology and epidemiology. Reviews in Medical Virology 10, 119-33.
2. Peiris, J. S. M., Tai, S. T., Poon, L. L. M. et al. (2003). Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361, 1319-25.
3. Oxford, J. S., Sefton, A., Jackson, R. et al. (2002). World War 1 may have allowed the emergence of 'Spanish' influenza. Lancet Infectious Diseases 2, 111-4.
4. Stuart-Harris, C. H., Schild, G. C. & Oxford, J. S. (1983). Influenza, the Viruses and the Disease. Edward Arnold, London, UK.
5. Von Itzstein, M., Wu, W. Y., Kok, G. B. et al. (1993). Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363, 118-23.
6. Monto, A. S., Fleming, D. M., Henry, D. et al. (1999). Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. Journal of Infectious Diseases 180, 254-61.
7. Hayden, F. G., Gubareva, L. V., Monto, A. S. et al. (2000). Inhaled zanamivir for the prevention of influenza in families. New England Journal of Medicine 343, 1282-9.
8. Welliver, R., Monto, A. S., Carewitc, O. et al. (2001). Effectiveness of oseltamivir in preventing influenza in household contacts. Journal of the American Medical Association 285, 748-54.
9. Hayden, F. G., Osterhaus, A. D. & Treanor, J. J. (1997). Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. New England Journal of Medicine 337, 874-80.
10. Hayden, F. G., Atmar, R. L. Schilling, M. et al. (1999). Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. New England Journal of Medicine 341, 1336-43.
11. Kim, C. U., Lew, W., Williams, M. A. et al. (1998). Structure-activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors. Journal of Medicinal Chemistry 41, 2451-60.
12. Oxford, J. S., Novelli, P., Sefton, A. et al. (2002). New millennium antivirals against pandemic and epidemic influenza: the neuraminidase inhibitors. Antiviral Chemistry and Chemotherapy 13, 205-17.
13. Elliott, M. (2001). Zanamivir: from drug design to the clinic. Philosophical Transactions of the Royal Society of London B 356, 1885-93.
14. Treanor, J. J., Hayden, F. G., Vrooman, P. S. et al. (2000). Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomised controlled trial. US Oral Neuraminidase Study Group. Journal of the American Medical Association 283, 1016-24.
15. Whitley, R. J., Hayden, F. G., Reisinger, K. S. et al. (2001). Oral oseltamivir treatment of influenza in children. Pediatric Infectious Disease Journal 20, 127-33.
16. Aoki, F. Y., Macleod, M. D., Paggiaro, P. et al. (2003). Early administration of oral oseltamivir increases the benefits of influenza treatment. Journal of Antimicrobial Chemotherapy 51, 123-9.
17. Oxford, J. S., Bossuyt, S. & Lambkin, R. (2003). A new infectious disease challenge: Urbani severe acute respiratory syndrome (SARS) associated coronavirus. Immunology 109, 1-3.